Claudia Mucciarini

1.8k total citations
27 papers, 531 citations indexed

About

Claudia Mucciarini is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Claudia Mucciarini has authored 27 papers receiving a total of 531 indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Pulmonary and Respiratory Medicine, 12 papers in Oncology and 6 papers in Cancer Research. Recurrent topics in Claudia Mucciarini's work include Renal cell carcinoma treatment (8 papers), Cancer Genomics and Diagnostics (6 papers) and Palliative Care and End-of-Life Issues (5 papers). Claudia Mucciarini is often cited by papers focused on Renal cell carcinoma treatment (8 papers), Cancer Genomics and Diagnostics (6 papers) and Palliative Care and End-of-Life Issues (5 papers). Claudia Mucciarini collaborates with scholars based in Italy, United States and Canada. Claudia Mucciarini's co-authors include Federica Bertolini, Massimo Federico, Riccardo Valli, Giulio Rossi, Gabriele Luppi, Luigi Marcheselli, Ivan Rashid, Claudia Cirilli, D. Turci and Angela Ragazzini and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and Scientific Reports.

In The Last Decade

Claudia Mucciarini

25 papers receiving 521 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Claudia Mucciarini Italy	11	308	211	196	163	67	27	531
Alessandra Maleddu Italy	12	278 0.9×	165 0.8×	183 0.9×	93 0.6×	92 1.4×	27	543
Hoon-Kyo Kim South Korea	10	688 2.2×	306 1.5×	270 1.4×	368 2.3×	60 0.9×	14	923
Ruey-Kuen Hsieh Taiwan	14	266 0.9×	295 1.4×	29 0.1×	104 0.6×	60 0.9×	44	664
Jorge Riera‐Knorrenschild Germany	10	885 2.9×	402 1.9×	224 1.1×	767 4.7×	48 0.7×	40	1.2k
R. Blanco Spain	9	227 0.7×	282 1.3×	48 0.2×	68 0.4×	44 0.7×	12	511
Kazım Uygun Türkiye	15	215 0.7×	312 1.5×	20 0.1×	155 1.0×	50 0.7×	56	683
Leire Arbea Spain	16	277 0.9×	399 1.9×	29 0.1×	321 2.0×	21 0.3×	49	706
James L. Leenstra United States	10	386 1.3×	431 2.0×	18 0.1×	164 1.0×	166 2.5×	18	752
Bong-Seog Kim South Korea	10	130 0.4×	121 0.6×	35 0.2×	60 0.4×	12 0.2×	15	296
Rohini Hawaldar India	10	202 0.7×	232 1.1×	25 0.1×	205 1.3×	68 1.0×	17	455

Countries citing papers authored by Claudia Mucciarini

Since Specialization

Citations

This map shows the geographic impact of Claudia Mucciarini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudia Mucciarini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudia Mucciarini more than expected).

Fields of papers citing papers by Claudia Mucciarini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claudia Mucciarini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudia Mucciarini. The network helps show where Claudia Mucciarini may publish in the future.

Co-authorship network of co-authors of Claudia Mucciarini

This figure shows the co-authorship network connecting the top 25 collaborators of Claudia Mucciarini. A scholar is included among the top collaborators of Claudia Mucciarini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claudia Mucciarini. Claudia Mucciarini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Bandieri, Elena, Eleonora Borelli, Sarah Bigi, et al.. (2024). Positive Psychological Well-Being in Early Palliative Care: A Narrative Review of the Roles of Hope, Gratitude, and Death Acceptance. Current Oncology. 31(2). 672–684. 6 indexed citations

Bandieri, Elena, Eleonora Borelli, Sarah Bigi, et al.. (2023). Stigma of Palliative Care among Patients with Advanced Cancer and Their Caregivers on Early Palliative Care. Cancers. 15(14). 3656–3656. 13 indexed citations

Masini, Cristina, Gabriele Carlinfante, Cinzia Iotti, et al.. (2021). Programmed death ligand-1 (PD-L1) expression in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in NIVES study.. Journal of Clinical Oncology. 39(15_suppl). 4558–4558. 1 indexed citations

Borelli, Eleonora, Sarah Bigi, Leonardo Potenza, et al.. (2021). Different semantic and affective meaning of the words associated to physical and social pain in cancer patients on early palliative/supportive care and in healthy, pain-free individuals. PLoS ONE. 16(3). e0248755–e0248755. 8 indexed citations

Procopio, Giuseppe, Alessia Mennitto, Massimo Di Maïo, et al.. (2021). Cabozantinib (Cabo) beyond progression improves survival in advanced renal cell carcinoma patients: The CABEYOND study (Meet-Uro 21).. Journal of Clinical Oncology. 39(6_suppl). 320–320.

Bandieri, Elena, Federico Banchelli, Fabrizio Artioli, et al.. (2019). Early versus delayed palliative/supportive care in advanced cancer: an observational study. BMJ Supportive & Palliative Care. 10(4). e32–e32. 27 indexed citations

Buti, Sebastiano, Melissa Bersanelli, Alessandro Leonetti, et al.. (2019). Treatment Outcome of metastatic lesions from renal cell carcinoma underGoing Extra-cranial stereotactic body radioTHERapy: The together retrospective study. Cancer Treatment and Research Communications. 22. 100161–100161. 22 indexed citations

Bandini, Marco, Elena Farè, Daniele Raggi, et al.. (2019). Sequencing chemotherapy and immune checkpoint inhibitors (ICI) in metastatic urothelial carcinoma (UC): Meet-Uro1 study.. Journal of Clinical Oncology. 37(15_suppl). e16013–e16013. 1 indexed citations

Masini, Cristina, Cinzia Iotti, Patrizia Ciammella, et al.. (2018). NIVES study: A phase II trial of nivolumab (NIVO) plus stereotactic body radiotherapy (SBRT) in II and III line of patients (pts) with metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology. 36(15_suppl). TPS4602–TPS4602. 4 indexed citations

10.

Passardi, Alessandro, Emanuela Scarpi, Fabio Gelsomino, et al.. (2017). Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial. Scientific Reports. 7(1). 10426–10426. 9 indexed citations

11.

Basso, Umberto, Antonella Facchinetti, Elisabetta Rossi, et al.. (2017). Prognostic role of circulating tumor cells-CTCs in metastatic renal cell carcinoma.. Journal of Clinical Oncology. 35(15_suppl). 4568–4568. 4 indexed citations

12.

Graziano, Francesco, Annamaria Ruzzo, Eliana Rulli, et al.. (2016). Dihydropyrimidine dehydrogenase (DPYD) gene polymorphisms profiling in colon cancer patients treated with adjuvant chemotherapy in the randomized phase III TOSCA trial. Annals of Oncology. 27. iv1–iv1. 1 indexed citations

13.

Franceschi, Enrico, Roberta Depenni, Alexandro Paccapelo, et al.. (2016). Which elderly newly diagnosed glioblastoma patients can benefit from radiotherapy and temozolomide? A PERNO prospective study. Journal of Neuro-Oncology. 128(1). 157–162. 20 indexed citations

14.

Passardi, Alessandro, Oriana Nanni, Davide Tassinari, et al.. (2015). Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Annals of Oncology. 26(6). 1201–1207. 121 indexed citations

15.

Bracarda, Sergio, Camillo Porta, C. Boni, et al.. (2012). Could Interferon Still Play a Role in Metastatic Renal Cell Carcinoma? A Randomized Study of Two Schedules of Sorafenib Plus Interferon-Alpha 2a (RAPSODY). European Urology. 63(2). 254–261. 21 indexed citations

16.

Fabbri, Francesca, Alessandro Passardi, Alessandra Ravaioli, et al.. (2011). Sequential treatment strategy for metastatic colorectal cancer: A phase III study of chemotherapy (CT) with or without bevacizumab (Bev) as first-line therapy followed by two phase III studies of CT alone or CT plus bev with or without cetuximab (Cetux) as second-line therapy (ITACa Study IRST 153 01).. Journal of Clinical Oncology. 29(15_suppl). e14161–e14161. 2 indexed citations

17.

Mucciarini, Claudia, Giulio Rossi, Federica Bertolini, et al.. (2007). Incidence and clinicopathologic features of gastrointestinal stromal tumors. A population-based study. BMC Cancer. 7(1). 230–230. 154 indexed citations

18.

Rossi, Giulio, Riccardo Valli, Federica Bertolini, et al.. (2005). PDGFR expression in differential diagnosis between KIT‐negative gastrointestinal stromal tumours and other primary soft‐tissue tumours of the gastrointestinal tract. Histopathology. 46(5). 522–531. 50 indexed citations

19.

Mucciarini, Claudia, et al.. (2004). Gastrointestinal stromal tumors (GIST): Evaluation of malignancy and prognosis in 113 cases retrieved from a population based Cancer Registry of Northern Italy. Journal of Clinical Oncology. 22(14_suppl). 4232–4232. 1 indexed citations

20.

Mucciarini, Claudia, Giulio Rossi, Federica Bertolini, et al.. (2004). Gastrointestinal stromal tumors (GIST): Evaluation of malignancy and prognosis in 113 cases retrieved from a population based Cancer Registry of Northern Italy. Journal of Clinical Oncology. 22(14_suppl). 4232–4232. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact